KR102468430B1 - 피리미디닐 티로신 키나아제 억제제 - Google Patents

피리미디닐 티로신 키나아제 억제제 Download PDF

Info

Publication number
KR102468430B1
KR102468430B1 KR1020217017552A KR20217017552A KR102468430B1 KR 102468430 B1 KR102468430 B1 KR 102468430B1 KR 1020217017552 A KR1020217017552 A KR 1020217017552A KR 20217017552 A KR20217017552 A KR 20217017552A KR 102468430 B1 KR102468430 B1 KR 102468430B1
Authority
KR
South Korea
Prior art keywords
compound
amino
chloro
oxo
bipiperidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217017552A
Other languages
English (en)
Korean (ko)
Other versions
KR20210072139A (ko
Inventor
브라이언 티. 홉킨스
패트릭 콘론
티모시 알. 찬
트레이시 제이. 젠킨스
슝웨이 차이
마이클 후모라
샹린 스
로스 에이. 밀러
앤드류 톰슨
Original Assignee
바이오젠 엠에이 인코포레이티드
선에시스 파마슈티컬스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오젠 엠에이 인코포레이티드, 선에시스 파마슈티컬스 인코포레이티드 filed Critical 바이오젠 엠에이 인코포레이티드
Priority to KR1020227039393A priority Critical patent/KR20220154850A/ko
Publication of KR20210072139A publication Critical patent/KR20210072139A/ko
Application granted granted Critical
Publication of KR102468430B1 publication Critical patent/KR102468430B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
KR1020217017552A 2012-06-08 2013-06-07 피리미디닐 티로신 키나아제 억제제 Active KR102468430B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227039393A KR20220154850A (ko) 2012-06-08 2013-06-07 피리미디닐 티로신 키나아제 억제제

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261657360P 2012-06-08 2012-06-08
US61/657,360 2012-06-08
KR1020207010675A KR20200043497A (ko) 2012-06-08 2013-06-07 피리미디닐 티로신 키나아제 억제제
PCT/US2013/044800 WO2013185084A1 (en) 2012-06-08 2013-06-07 Pyrimidinyl tyrosine kinase inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207010675A Division KR20200043497A (ko) 2012-06-08 2013-06-07 피리미디닐 티로신 키나아제 억제제

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227039393A Division KR20220154850A (ko) 2012-06-08 2013-06-07 피리미디닐 티로신 키나아제 억제제

Publications (2)

Publication Number Publication Date
KR20210072139A KR20210072139A (ko) 2021-06-16
KR102468430B1 true KR102468430B1 (ko) 2022-11-21

Family

ID=49712704

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020217017552A Active KR102468430B1 (ko) 2012-06-08 2013-06-07 피리미디닐 티로신 키나아제 억제제
KR1020207010675A Ceased KR20200043497A (ko) 2012-06-08 2013-06-07 피리미디닐 티로신 키나아제 억제제
KR1020157000393A Expired - Fee Related KR102102587B1 (ko) 2012-06-08 2013-06-07 피리미디닐 티로신 키나아제 억제제
KR1020227039393A Ceased KR20220154850A (ko) 2012-06-08 2013-06-07 피리미디닐 티로신 키나아제 억제제

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020207010675A Ceased KR20200043497A (ko) 2012-06-08 2013-06-07 피리미디닐 티로신 키나아제 억제제
KR1020157000393A Expired - Fee Related KR102102587B1 (ko) 2012-06-08 2013-06-07 피리미디닐 티로신 키나아제 억제제
KR1020227039393A Ceased KR20220154850A (ko) 2012-06-08 2013-06-07 피리미디닐 티로신 키나아제 억제제

Country Status (30)

Country Link
US (6) US9394277B2 (enExample)
EP (3) EP3753934A1 (enExample)
JP (6) JP6214643B2 (enExample)
KR (4) KR102468430B1 (enExample)
CN (3) CN104540385B (enExample)
AR (1) AR091273A1 (enExample)
AU (5) AU2013271407B2 (enExample)
BR (2) BR112014030655B1 (enExample)
CA (2) CA3108186A1 (enExample)
CY (1) CY1120638T1 (enExample)
DK (1) DK2858499T3 (enExample)
EA (2) EA027823B1 (enExample)
ES (2) ES2684268T3 (enExample)
HR (1) HRP20181294T1 (enExample)
HU (1) HUE039897T2 (enExample)
IL (2) IL235938B (enExample)
IN (1) IN2014DN10576A (enExample)
LT (1) LT2858499T (enExample)
MX (2) MX363672B (enExample)
NZ (1) NZ702715A (enExample)
PH (2) PH12018501463B1 (enExample)
PL (1) PL2858499T3 (enExample)
PT (1) PT2858499T (enExample)
RS (1) RS57978B1 (enExample)
SG (2) SG11201408173WA (enExample)
SI (1) SI2858499T1 (enExample)
SM (1) SMT201800442T1 (enExample)
TW (3) TWI792158B (enExample)
WO (1) WO2013185084A1 (enExample)
ZA (1) ZA201409255B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI557127B (zh) 2009-09-04 2016-11-11 百健Ｍａ公司 布魯頓氏酪胺酸激酶抑制劑
US9273028B2 (en) 2010-10-29 2016-03-01 Biogen Ma Inc. Heterocyclic tyrosine kinase inhibitors
AR091273A1 (es) * 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
EP2858500A4 (en) 2012-06-08 2016-04-06 Biogen Ma Inc BRUTON TYROSINE KINASE HEMMER
HRP20181109T1 (hr) * 2013-12-11 2018-11-02 Biogen Ma Inc. Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
WO2015151006A1 (en) 2014-03-29 2015-10-08 Lupin Limited Substituted purine compounds as btk inhibitors
WO2015170266A1 (en) 2014-05-07 2015-11-12 Lupin Limited Substituted pyrimidine compounds as btk inhibitors
MX393057B (es) * 2014-10-24 2025-03-24 Bristol Myers Squibb Co Compuestos de indol carboxamida útiles como inhibidores de cinasas.
CA3031443A1 (en) * 2016-07-21 2018-01-25 Biogen Ma Inc. Succinate of pyrimidinyl derivatives and solid forms thereof as bruton's tyrosine kinase inhibitors
US20210113568A1 (en) 2018-04-27 2021-04-22 Ono Pharmaceutical Co., Ltd. PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT
CA3108065C (en) 2018-07-31 2025-10-07 Loxo Oncology, Inc. SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
US20240216330A1 (en) 2021-04-02 2024-07-04 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
WO2023081709A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Vecabrutinib for the treatment of graft-versus-host disease
US20260083848A1 (en) 2021-11-03 2026-03-26 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
EP4448523A1 (en) 2021-12-14 2024-10-23 Crossfire Oncology Holding B.V. Macrocyclic btk inhibitors
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024246287A1 (en) 2023-06-02 2024-12-05 Crossfire Oncology Holding B.V. Medical use of a macrocyclic reversible btk inhibitor
WO2024256574A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors
WO2024256568A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Salt and crystal forms of a macrocyclic btk inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011029046A1 (en) 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Bruton's tyrosine kinase inhibitors
US20120040961A1 (en) 2009-01-06 2012-02-16 Dana-Farber Cancer Institute Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
US20120058996A1 (en) 2008-12-19 2012-03-08 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1624A (en) * 1840-06-10 Cooking-stove
US4528138A (en) 1984-06-20 1985-07-09 E. R. Squibb & Sons, Inc. 16-Keto-17-substituted thia-17-alkyl(or alkenyl or alkynyl) androstenes
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6919178B2 (en) 2000-11-21 2005-07-19 Sunesis Pharmaceuticals, Inc. Extended tethering approach for rapid identification of ligands
IL151552A0 (en) 2000-03-17 2003-04-10 Bristol Myers Squibb Pharma Co Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
MY145722A (en) 2000-04-27 2012-03-30 Abbott Lab Diazabicyclic central nervous system active agents
OA12292A (en) 2000-06-26 2003-11-11 Pfizer Prod Inc PyrroloÄ2,3-dÜpyrimidine compounds as immunosuppressive agents.
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
AU2002363236A1 (en) * 2001-10-30 2003-05-12 Millennium Pharmaceuticals, Inc. Compounds, pharmaceutical compositions and methods of use therefor
CA2464934A1 (en) 2001-10-31 2003-05-08 Bayer Healthcare Ag Pyrimido [4,5-b] indole derivatives
RS20050532A (sr) 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija
WO2005037825A2 (en) 2003-10-14 2005-04-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein kinase inhibitors
US20080253960A1 (en) * 2004-04-01 2008-10-16 The Trustees Of The University Of Pennsylvania Center For Technology Transfer Lipoprotein-Based Nanoplatforms
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
FR2870541B1 (fr) 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
AR050865A1 (es) 2004-09-09 2006-11-29 Sanofi Aventis Derivados de 2- morfolino-4-pirimidona
DE602005023763D1 (de) * 2004-11-04 2010-11-04 Vertex Pharma Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
US7700597B2 (en) 2004-12-03 2010-04-20 Schering Corporation Substituted piperazines as CB1 antagonists
AU2005322085B2 (en) 2004-12-28 2012-07-19 Exelixis, Inc. [1H-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70S6K, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
WO2006071875A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US7423043B2 (en) * 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
US20060281700A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20060281764A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Aminopyrimidines as kinase modulators
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
CA2634235A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
US20080076924A1 (en) 2006-06-30 2008-03-27 Patrick Betschmann Piperazines as P2X7 antagonists
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
EP2059305A2 (en) 2006-07-26 2009-05-20 Novartis Ag Inhibitors of undecaprenyl pyrophosphate synthase
JP2010502751A (ja) * 2006-09-11 2010-01-28 シージーアイ ファーマシューティカルズ，インコーポレイティド キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
CA2679807A1 (en) * 2007-03-02 2008-09-12 Schering Corporation Piperidine derivatives and methods of use thereof
WO2008116064A2 (en) 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
WO2008144253A1 (en) 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
BRPI0811898A2 (pt) 2007-06-01 2019-09-24 Glaxosmithkline Llc composto, composição farmacêutica, métodos para tratar um neoplasma suscetível e um câncer em um mamífero, processo para preparar um composto, e, uso de um composto.
ES2420846T3 (es) * 2008-02-05 2013-08-27 F. Hoffmann-La Roche Ag Nuevas piridinonas y piridazinonas
EP2283358B1 (en) 2008-04-29 2015-04-22 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
CN102159214A (zh) 2008-07-16 2011-08-17 药品循环公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
WO2010068788A1 (en) * 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Heterocyclic amides as btk inhibitors
JP2012528102A (ja) 2009-05-25 2012-11-12 サンド・アクチエンゲゼルシヤフト セフトビプロールメドカリルの製造方法
WO2011029043A1 (en) 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
US8685880B2 (en) * 2010-06-30 2014-04-01 Chevron U.S.A. Inc. On-site drying of aqueous salt for ionic liquid make-up
US9273028B2 (en) 2010-10-29 2016-03-01 Biogen Ma Inc. Heterocyclic tyrosine kinase inhibitors
EP2858500A4 (en) 2012-06-08 2016-04-06 Biogen Ma Inc BRUTON TYROSINE KINASE HEMMER
AR091273A1 (es) * 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
WO2015089327A1 (en) 2013-12-11 2015-06-18 Biogen Idec Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
HRP20181109T1 (hr) 2013-12-11 2018-11-02 Biogen Ma Inc. Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
US20170298446A1 (en) 2014-10-03 2017-10-19 Ohio State Innovation Foundation Biomarkers of bruton tyrosine kinase inhibitor resistance
CA3031443A1 (en) * 2016-07-21 2018-01-25 Biogen Ma Inc. Succinate of pyrimidinyl derivatives and solid forms thereof as bruton's tyrosine kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120058996A1 (en) 2008-12-19 2012-03-08 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
US20120040961A1 (en) 2009-01-06 2012-02-16 Dana-Farber Cancer Institute Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
WO2011029046A1 (en) 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Bruton's tyrosine kinase inhibitors

Also Published As

Publication number Publication date
JP2023052415A (ja) 2023-04-11
US10618887B2 (en) 2020-04-14
AU2013271407A1 (en) 2015-01-22
EP2858499A4 (en) 2016-01-20
KR20150036020A (ko) 2015-04-07
EP3385263A1 (en) 2018-10-10
ZA201409255B (en) 2015-12-23
IL235938A0 (en) 2015-02-01
MX363672B (es) 2019-03-29
KR20220154850A (ko) 2022-11-22
HK1209284A1 (en) 2016-04-01
EA201492056A1 (ru) 2015-05-29
KR20210072139A (ko) 2021-06-16
CA2875799C (en) 2021-03-23
EP2858499B1 (en) 2018-05-16
MX385593B (es) 2025-03-18
KR102102587B1 (ko) 2020-04-22
US20230174511A1 (en) 2023-06-08
SMT201800442T1 (it) 2018-09-13
HRP20181294T1 (hr) 2018-10-05
SI2858499T1 (sl) 2018-10-30
BR112014030655B1 (pt) 2021-04-20
TW202142535A (zh) 2021-11-16
EP3753934A1 (en) 2020-12-23
KR20200043497A (ko) 2020-04-27
EA201790418A1 (ru) 2017-11-30
RS57978B1 (sr) 2019-01-31
TWI792158B (zh) 2023-02-11
CN109305959B (zh) 2022-02-08
PL2858499T3 (pl) 2019-03-29
CN104540385B (zh) 2018-06-05
JP2021073299A (ja) 2021-05-13
US20160304494A1 (en) 2016-10-20
JP2017193583A (ja) 2017-10-26
JP6214643B2 (ja) 2017-10-18
PH12018501463A1 (en) 2019-03-04
US20240417389A1 (en) 2024-12-19
BR112014030655A2 (pt) 2017-06-27
MX2019003618A (es) 2019-07-18
TWI719209B (zh) 2021-02-21
ES2834333T3 (es) 2021-06-17
TWI592406B (zh) 2017-07-21
EP2858499A1 (en) 2015-04-15
ES2684268T3 (es) 2018-10-02
CN113549055A (zh) 2021-10-26
EA027823B1 (ru) 2017-09-29
AR091273A1 (es) 2015-01-21
JP2021073298A (ja) 2021-05-13
AU2019203476B2 (en) 2021-01-28
SG11201408173WA (en) 2015-01-29
EP3385263B1 (en) 2020-07-22
WO2013185084A1 (en) 2013-12-12
BR112014030655A8 (pt) 2018-01-02
AU2022275504A1 (en) 2023-01-05
LT2858499T (lt) 2018-09-10
IN2014DN10576A (enExample) 2015-08-28
MX2014015044A (es) 2015-09-22
US9944622B2 (en) 2018-04-17
PH12014502699A1 (en) 2015-02-02
US20150158843A1 (en) 2015-06-11
AU2013271407B2 (en) 2016-12-08
JP2015518903A (ja) 2015-07-06
CN104540385A (zh) 2015-04-22
US20210017155A1 (en) 2021-01-21
US20190047986A1 (en) 2019-02-14
CA3108186A1 (en) 2013-12-12
DK2858499T3 (en) 2018-08-20
TW201410668A (zh) 2014-03-16
AU2017201536A1 (en) 2017-03-23
HUE039897T2 (hu) 2019-02-28
IL235938B (en) 2020-10-29
JP2019077728A (ja) 2019-05-23
BR122021002178B1 (pt) 2022-03-22
CA2875799A1 (en) 2013-12-12
AU2017201536B2 (en) 2019-03-07
PH12018501463B1 (en) 2024-03-27
SG10201708535UA (en) 2017-11-29
US9394277B2 (en) 2016-07-19
AU2021202412A1 (en) 2021-05-20
PT2858499T (pt) 2018-10-24
IL277951A (en) 2020-11-30
CY1120638T1 (el) 2019-12-11
CN109305959A (zh) 2019-02-05
NZ702715A (en) 2016-11-25
TW201805279A (zh) 2018-02-16
AU2019203476A1 (en) 2019-06-06
PH12014502699B1 (en) 2015-02-02

Similar Documents

Publication Publication Date Title
AU2019203476B2 (en) Pyrimidinyl tyrosine kinase inhibitors
HK40043767A (en) Pyrimidinyl derivatives useful as tyrosine kinase inhibitors
HK1262106B (en) Pyrimidinyl tyrosine kinase inhibitors
HK1262106A1 (en) Pyrimidinyl tyrosine kinase inhibitors

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210608

Application number text: 1020207010675

Filing date: 20200413

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210708

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211022

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220818

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20221110

Application number text: 1020207010675

Filing date: 20200413

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20221115

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20221116

End annual number: 3

Start annual number: 1

PG1601 Publication of registration